Multiple Myeloma Associated IgA Pemphigus: Treatment With Bortezomib- and Lenalidomide-Based Regimen

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

SZTURZ Petr ADAM Zdeněk KLINCOVÁ Mária FEIT Josef KREJČÍ Marta POUR Luděk ZAHRADOVÁ Lenka VAŠKŮ Vladimír HÁJEK Roman MAYER Jiří

Year of publication 2011
Type Article in Periodical
Magazine / Source Clinical Lymphoma, Myeloma & Leukemia
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1016/j.clml.2011.06.014
Field Oncology and hematology
Keywords Autoimmunity; Bortezomib; IgA pemphigus; Lenalidomide; Multiple myeloma; Paraproteinemia
Description Generally, monoclonal immunoglobulins do not bind an autologous antigen, except for some cases, when it causes immune damage to body’s own tissues. Vesiculopustulous dermatitis associated with immunoglobulin (Ig) A deposition in the epidermis represents an autoimmune skin manifestation of monoclonal gammopathy. It is commonly referred to as subcorneal pustular dermatosis type of IgA pemphigus.1 In our previous work, we reported on complete and long-term remission of multiple myeloma associated IgA pemphigus after treatment with a bortezomib (Velcade) based regimen.2 In this work, to our knowledge, we are the first to publish a convincing clinical remission and excellent drug tolerance of a subsequent lenalidomide (Revlimid) based regimen used in the same patient for management of the relapsed disease.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info